rVSV∆G-SEBOV-GP / IAVI, BARDA - LARVOL DELTA

Combatting the increase in filovirus outbreaks: the importance of preparedness and partnership in responding to Uganda's 2025 Sudan virus outbreak (ASTMH 2025) - "The vaccine is based on the recombinant vesicular stomatitis virus (rVSV) viral vector platform, the same technology utilized in Merck's licensed ERVEBO® vaccine against EBOV (Ebola Zair)...This experience highlights a much-needed partnership model where investigational emerging infectious disease vaccine candidates are available for testing as part of and alongside an outbreak response. This response was achieved through collaboration and coordination of efforts between multiple stakeholders and global health organizations, efficient communication among partners, pre-approved protocols and contracts, the availability of the vaccine doses in-country and previously generated preclinical and clinical data."

Late-breaking abstract • Ebola Virus Disease • Hematological Disorders • Infectious Disease

Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: International AIDS Vaccine Initiative | Active, not recruiting ➔ Completed

Trial completion • Ebola Virus Disease • Infectious Disease